Table 1

Efficacy of CDK4/6 inhibitors in the preoperative setting

ReferenceTherapyPhasePatient characteristicsNumber of patientsResponse rate (%)Grade 3/4 toxicity
Chow et al 11 Palbociclib + letrozole (4 months preoperatively)II, OOTR-N007OR+, HER2- postmenopausal
tumour >2 cm, not T3 N1, T4 or N 2,3

11 (9 completed) of 45 planned; the study is ongoingpCR 11% PR 78%, RR 89%44% neutropenia
Ma et al 58 Anastrozole
+ goserelin (if premenopausal) +
palbociclib
IIOR+, HER2-
stage 2 or 3
50 (40 evaluable)Complete cell cycle arrest 85%NR
  • HER2, human epidermal receptor 2; NR, not reported; OR, oestrogen receptor; ORR, overall response rate; pCR, pathological complete response; PR, partial response; RR, response rate.